Spiro-thiazolones
AssigneeHoffmann-LaRoche Inc.
InventorsCosimo Dolente, Bernhard Fasching, Valerie Runtz-Schmitt, Patrick Schnider
Life of this patent
Estimating the term…
Abstract
Spiro-thiazolones of formula I wherein X1, X2, X3, X4, R2, R3, R4, R5, R6 and R7 are as defined herein, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
Claims12
A compound of formula I,
- wherein
- X1 C—R1 or N;
- X2 C—R1 or N;
- X3 C—R1 or N;
- X4 C—R1 or N;
- whereby
- i) one of X1, X2, X3 is C—R1 and X4 is N,
- ii) each of X1, X2, X3 and X4 is C—R1;
- R1 each separately is selected from the group consisting of hydrogen, halogen, hydroxy, C1-6-alkyl and C1-6-alkoxy;
- R2 is selected from the group consisting of hydrogen and C1-6-alkyl;
- R3 is selected from the group consisting of hydrogen and C1-6-alkyl;
- or R2 and R3 together are ═O;
- R4 is hydrogen;
- R5 is selected from the group consisting of
- i) hydrogen,
- ii) C3-7-cycloalkyl,
- iii) C3-7-cycloalkyl substituted by one or more substituents individually selected from halogen and C1-6-alkyl,
- iv) C1-6-alkyl,
- v) C1-6-alkyl substituted by one or more substituents individually selected from amino, halogen, hydroxy, C1-6-alkoxy, —O—C(═O)—C1-6-alkyl, NH(C═O)O—C1-6-alkyl and —O—Si(C1-6-alkyl)3,
- vi) aryl,
- vii) aryl substituted by one or more substituents individually selected from halogen and C1-6-alkyl,
- viii) heteroaryl, and
- ix) heteroaryl substituted by one or more substituents individually selected from halogen and C1-6-alkyl;
- R6 is selected from the group consisting of
- i) C1-6-alkyl,
- ii) C1-6-alkyl substituted by one or more substituents individually selected from amino, halogen, C1-6-alkoxy, —O—C(═O)C1-6-alkyl, N(C1-6-alkyl)2, NH(C═O)O—C1-6-alkyl, SO2—C1-6-alkyl and —O—Si(C1-6-alkyl)3;
- iii) C2-6-alkenyl
- iv) aryl,
- v) aryl substituted by one or more substituents individually selected from halogen and C1-6-alkyl;
- vi) C3-9-cycloalkyl,
- vii) C3-9-cycloalkyl substituted by one or more substituents individually selected from —(C═O)O—C1-6-alkyl, oxo, C1-6-alkoxy and C1-6-alkyl;
- viii) heterocyclyl,
- ix) heteroaryl, and
- x) heteroaryl substituted by one or more substituents individually selected from halogen, C1-6-alkoxy and C1-6-alkyl;
- or R5 and R6 together are selected from the group consisting of
- i) C3-9-cycloalkyl, optionally fused with one or two phenyl,
- ii) C3-9-cycloalkyl, optionally fused with phenyl, wherein the phenyl moiety is substituted by one or more substituents individually selected from halogen, hydroxy, (C═O)O—C1-6-alkyl, C1-6-alkoxy and C1-6-alkyl,
- iii) C3-6-cycloalkenyl,
- iv) heterocyclyl, optionally fused with one or two phenyl, and
- v) heterocyclyl, optionally fused with phenyl, wherein the heterocyclyl moiety is substituted by one or more substituents individually selected from oxo, (C═O)O—C1-6-alkyl and SO2—C1-6-alkyl or wherein the phenyl moiety is substituted by one or more halogen;
- R7 is hydrogen;
- or R4 and R7 together are —(CH2)n—;
- and
- n is 2, 3 or 4;
- or pharmaceutically acceptable salts thereof.
A method for treating autistic spectrum disorders, the method comprising administering an effective amount of a compound of formula I to a human being or animal in need thereof.
Dependencies are inferred from the claim text.